Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): later-stage trial registry
1 of 2 indexed Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): 2 US clinical trials tracked, 1 recruiting.
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is UCB Biopharma SRL, running 1 of these trials.
Enrollment posture brief
Registry condition myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad
OPEN 1 | RECR 50% | LATE 2 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Hoffmann-La Roche
NCT05271409
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
UCB Biopharma SRL
NCT05063162
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- UCB Biopharma SRL sponsors the most Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) trials on record, review their full trial history before evaluating a specific study. See UCB Biopharma SRL's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) condition card totals 2 registered trials; most-linked intervention Placebo; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.